Levy-Toledano S, Maclouf J, Caen J, Bara L, Lecrubier C, Samama M
J Pharmacol. 1983 Apr-Jun;14(2):141-50.
The effect of flurbiprofen has been studied on the platelet aggregation of a human platelet rich plasma in the presence of 3 different inducers: ADP, collagen and arachidonic acid. Flurbiprofen is a potent inhibitor of platelet aggregation as compared to aspirin (160 to 2200 more potent). This inhibition was also found using isolated platelets stimulated by arachidonic acid where the suppression of the thromboxane synthesis was accompanied by the inhibition of 14C-serotonin release as well as of aggregation. The administration of flurbiprofen to rabbits, 1 and 3 mg/kg during 3 days was followed by an inhibition of the collagen-induced platelet reactivity. The aortic prostacyclin synthesis as studied by its biological activity was also inhibited at 3 mg/kg (p less than 0,01) but less significantly at 1 mg/kg. The more potent action of flurbiprofen compared to that of aspirin as well as its rapid reversibility would allow the use of this drug for the inhibition of some of the platelet functions.
在存在3种不同诱导剂(二磷酸腺苷、胶原蛋白和花生四烯酸)的情况下,研究了氟比洛芬对人富血小板血浆血小板聚集的影响。与阿司匹林相比,氟比洛芬是一种强效的血小板聚集抑制剂(效力强160至2200倍)。在使用花生四烯酸刺激的分离血小板时也发现了这种抑制作用,其中血栓素合成的抑制伴随着14C - 5 -羟色胺释放以及聚集的抑制。给兔子连续3天给予1和3mg/kg的氟比洛芬后,胶原蛋白诱导的血小板反应性受到抑制。通过其生物活性研究发现,主动脉前列环素合成在3mg/kg时也受到抑制(p小于0.01),但在1mg/kg时抑制作用较弱。与阿司匹林相比,氟比洛芬更强效的作用及其快速可逆性使得该药物可用于抑制某些血小板功能。